In 2025, Appili submitted multiple U.S. funding proposals representing up to US$90M. If awarded, the funds would support critical development activities across the portfolio. Awards from proposals are anticipated to be announced in Q1 2026.

$APLI $APLIF

appilitherapeutics.com

CEO, Don Cilla will represent Appili at the 2025 @bardagov.bsky.social Innovation Symposium on Nov 20 in DC!

Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures.
drive.hhs.gov/innovation20...

$APLI $APLIF

#BARDAInnovation #Biotech

ICYMI: Appili & Vitalex secured a US $40M NIAID contract to advance VXV-01, a first-in-class fungal vaccine. With no approved fungal vaccines for humans, VXV-01 aims to fill an urgent unmet need!

#Biotech #Innovation #Appili

$APLI $APLIF

Appili has secured a new NIAID contract worth up to US $40M — bringing our total government funding awards to US $74M, with US $97M more in pending applications.

$APLI $APLIF

#biotech #funding #innovation #Appili

appilitherapeutics.com/2025/10/01/a...

“Collaboration across the globe is essential for tackling today’s urgent infectious disease challenges”

At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701.

appilitherapeutics.com/contact/

$APLI $APLIF

On Friday at 11:30AM, @appili.bsky.social CEO, Dr. Don Cilla joins Aditxt CEO, Amro Albanna in a Weekly Update, to discuss the transaction status & recent highlights, including $117M in funding applications to advance infectious disease treatments.

us06web.zoom.us/webinar/regi...
$APLI $APLIF $ADTX

Appili’s leadership team will join over 3000 attendees at The World Vaccine Congress in D.C.!

This year, we look forward to gathering with industry leaders, and share recent developments including ATI-1701, our biodefense vaccine candidate.

$APLI $APLIF #WVCUSA #WVC2025 #WVCDC

Last week, Lab Manager, Brandon Green represented Appili at @umkc.bsky.social’s NextGen PATHWAYS Symposium and presented research on ATI-1701.

Appili is proud of our incredible team at the UMKC lab, and excited about progress being made in infectious disease research.

$APLI $APLIF